Active BMN 111: Daily subcutaneous injection of 15 ug/kg of BMN 111 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 276 | 軟骨無形成症 | 1 |
276. 軟骨無形成症
臨床試験数 : 46 / 薬物数 : 29 - (DrugBank : 6) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 30
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03989947 (ClinicalTrials.gov) | June 12, 2019 | 22/5/2019 | An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia | A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia | Achondroplasia | Drug: Active BMN 111: Daily subcutaneous injection of 15 ug/kg of BMN 111 | BioMarin Pharmaceutical | NULL | Enrolling by invitation | 15 Months | N/A | All | 70 | Phase 2 | United States;Australia;Japan;United Kingdom |